25 /100
LOW RISK
Score updated Jul 14, 2026

GPCR — Structure Therapeutics Inc. Dilution Risk Tracker

Track GPCR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GPCR — Get alerts when the score changes →

As of July 14, 2026, Structure Therapeutics Inc. (GPCR) has a DilutionWatch DilutionScore of 25/100, rated LOW dilution risk. Structure Therapeutics Inc. has a market capitalization of $2.80B, 213.22M shares outstanding, 198 institutional holders tracked. Key dilution vectors include approximately 192 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for GPCR.
🔔 Track GPCR — Get forecast alerts →

💹 Market Data

Market Cap$2.80B
Shares Outstanding213.22M
FloatN/A
Cash$1.46B
Debt$6.49M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 17.4% shares (2026Q1 vs prior)
198 institutional holders · 78.38M shares
#1 Avoro Capital Advisors LLC 13.11M shares
#2 FMR LLC 8.40M shares
#3 WELLINGTON MANAGEMENT GROUP LLP 7.26M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest6.13M
Days to Cover6.3
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2023
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for GPCR Shareholders

Structure Therapeutics Inc. (GPCR) has a DilutionScore of 25/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for GPCR shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for GPCR in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for GPCR alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track GPCR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GPCR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for GPCR
📊 GPCR FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 GPCR Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.